Ascentage Pharma Group InternationalvsAmgen

AAPG and AMGN stock compared: price, dividend, valuation and results, from SEC filings.

AAPG

Ascentage Pharma Group International

$11.97

Value $1.1B

-3.78%
AAPG's page

AMGN

Amgen Inc.

$435.64

Value $235B

-0.72%
AMGN's page

Ascentage Pharma Group International (AAPG) has a market value of $1.1B and Amgen (AMGN) $235B. Over the last year, with dividends, AAPG moved -62.8% and AMGN +31.5%. Dividend yield: AAPG none, AMGN 2.31%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AAPG$1.1B

    AMGN$235B

    AMGN is 210 times AAPG

  • Revenue, 12 months

    AAPG$82M

    AMGN$38.9B

    AMGN is 474 times AAPG

  • Net income, 12 months

    AAPG-$178M

    AMGN$9.4B

  • Operating margin

    AAPG-215.3%

    AMGN32.4%

    247.7 points apart

  • ROIC

    AAPG-73.2%

    AMGN16.2%

    89.4 points apart

  • P/E

    AAPG–

    AMGN25.0

  • Dividend yield

    AAPG0.0%

    AMGN2.3%

    2.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AAPG-62.8%

AMGN+31.5%

50100DecFebAprJunAugOct
Returns by period
PeriodAAPGWith dividendsAMGNWith dividends
1 year since November 19, 2025-62.8%Price -62.8%+31.5%Price +27.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AAPGAscentage Pharma Group InternationalAMGNAmgen

Valuation

AAPGAMGN
Valuation
Price$11.97$435.64
Market value$1.1B$235B
Enterprise value (EV)$946M$276B
P/E–25.0
P/E, 5-year median–23.0
P/B5.916.4
EV/EBIT–21.9
Free cash flow yield–4.1%

Results and growth

AAPGAMGN
Results and growth
Revenue, 12 months$82M$38.9B
Net income, 12 months-$178M$9.4B
Free cash flow, 12 months-$172M$9.6B
Earnings per share, 12 months-$2.00$17.25
Revenue growth, year on year-41.5%10.0%
Revenue growth a year, past+39.9%over 3 years+7.6%over 5 years
EPS growth a year, past–+2.9%over 5 years

Margins and returns on capital

AAPGAMGN
Margins and returns on capital
Gross margin91.5%70.9%
Operating margin-215.3%32.4%
Net margin-216.5%24.1%
ROIC-73.2%16.2%
ROE-93.2%87.8%

Balance sheet

AAPGAMGN
Balance sheet
Cash$171M$13.2B
Total debt–$54.0B
Net debt / EBITDA–2.3
Interest cover–4.8×

Dividends and buybacks

AAPGAMGN
Dividends and buybacks
Dividend yield–2.3%
Dividend per share, 12 months–$10.08
Dividend growth a year, past–+8.1%over 5 years
Buyback yield––
Shareholder yield–2.3%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AAPG or AMGN

Didn't find what you were looking for?

Ask us
Which is bigger, Ascentage Pharma Group International or Amgen?

By market value, Amgen ($235B) is about 210.2 times Ascentage Pharma Group International ($1.1B), at today's prices.

How did AAPG and AMGN stock do over the last 1 years?

Since November 19, 2025, AAPG's price moved -62.8% and AMGN's +27.2%. With dividends: AAPG -62.8% (-62.8% a year), AMGN +31.5% (+31.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, AAPG or AMGN?

The dividend yield at today's price is none for Ascentage Pharma Group International and 2.31% for Amgen. Over the last twelve months they paid – and $10.08 per share.

Which has the higher profit margins, Ascentage Pharma Group International or Amgen?

Over the last twelve months, the net margin was -216.5% for Ascentage Pharma Group International and 24.1% for Amgen, and the operating margin -215.3% and 32.4%. Revenue was $82M and $38.9B.

Which is the better investment, Ascentage Pharma Group International or Amgen?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.